The value of time-in-range as a glycemic biomarker: Part 1

HbA1c is still regarded as the current gold standard for glycemic control. Although its advantages have been known for 35 years, as Continuous Glucose Monitoring (CGM) became more widely utilized, its drawbacks became more apparent. The amount of data from CGM indicates the need for measurements other than HbA1c to comply with these limitations. The advent of CGM emerged slowly and progressively as a result of its significance providing a deeper insight into glycemic control in people with diabetes as well as its link to better clinical outcomes. Time-in-range is an intuitive parameter of evaluating glycemic data and status, which simply denotes the proportion of time that a person’s glucose level is within a desired target range (usually 3.9–10.0 mmol/l). Routine treatment has substantially changed CGM and time-in-range for both diabetic patients and healthcare workers. 

Dr. Tadej Battelino of University Medical Center Ljubljana and University of Ljubljana, Slovenia, discusses the value of TIR as a glycemic biomarker, the function of CGM and its advantages, and other topics in this episode.